Analyst Ratings for Cardiome Pharma (CRME)
CRME Rating Summary
CRME Price Target Summary
- Highest: $1.00 (Leerink Swann)
- Lowest: $0.85 (Canaccord Genuity)
- Average: $0.93
Overall Rating:
NEUTRAL
Rating Trend:
=
Avg. $ Target:
$0.93 (-52.3%)
| Date | Firm | Type | Rating (Past) |
PT (Past) |
Start $ | End $ | % Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/28/2012 | Canaccord Genuity | Upgrade | Hold (N/A) |
0.85 (N/A) |
0.74 | 1.94 | 162.16% | Details |
| 3/20/2012 | Leerink Swann | Downgrade | Market Perform (N/A) |
1.00 (N/A) |
0.88 | 1.94 | 120.45% | Details |
| 3/19/2012 | BMO Capital | Downgrade | Market Perform (N/A) |
N/A (N/A) |
0.93 | 1.94 | 108.6% | Details |
| 4/27/2011 | RBC Capital | Upgrade | Outperform (N/A) |
N/A (N/A) |
4.41 | 1.94 | -56.01% | Details |
| 2/7/2011 | Barclays » Updated 3/11/2011 |
Downgrade | Equalweight (N/A) |
N/A (N/A) |
6.83 | 1.94 | -71.6% | Details |
| 12/8/2010 | Wedbush | New Coverage | Outperform (N/A) |
N/A (N/A) |
5.82 | 1.94 | -66.67% | Details |
